MetLife Investment Management’s Collegium Pharmaceutical COLL Stock Holding History

MetLife Investment Management’s Portfolio COLL Stock Details COLL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$686K	Buy	18,958 +632	+3%	+$21.6K	﹤0.01%	1742
2026 Q1	$606K	Buy	18,326 +565	+3%	+$23.9K	﹤0.01%	1661
2025 Q4	$822K	Sell	17,761 -1,758	-9%	-$73.6K	﹤0.01%	1539
2025 Q3	$683K	Hold	19,519	–	–	﹤0.01%	1662
2025 Q2	$577K	Hold	19,519	–	–	﹤0.01%	1604
2025 Q1	$583K	Sell	19,519 -468	-2%	-$14.3K	﹤0.01%	1649
2024 Q4	$573K	Buy	19,987 +1,558	+8%	+$51.6K	﹤0.01%	1728
2024 Q3	$712K	Hold	18,429	–	–	﹤0.01%	1588
2024 Q2	$593K	Buy	18,429 +1,847	+11%	+$64K	﹤0.01%	1625
2024 Q1	$644K	Sell	16,582 -1,079	-6%	-$37.8K	﹤0.01%	1542
2023 Q4	$544K	Hold	17,661	–	–	﹤0.01%	1638
2023 Q3	$395K	Hold	17,661	–	–	﹤0.01%	1777
2023 Q2	$380K	Hold	17,661	–	–	﹤0.01%	1881
2023 Q1	$424K	Hold	17,661	–	–	﹤0.01%	1746
2022 Q4	$410K	Sell	17,661 -2,676	-13%	-$54K	﹤0.01%	1772
2022 Q3	$326K	Hold	20,337	–	–	﹤0.01%	1942
2022 Q2	$360K	Sell	20,337 -2,350	-10%	-$39.5K	﹤0.01%	1890
2022 Q1	$462K	Buy	22,687 +8,655	+62%	+$164K	﹤0.01%	1819
2021 Q4	$262K	Hold	14,032	–	–	﹤0.01%	1885
2021 Q3	$277K	Hold	14,032	–	–	﹤0.01%	1875
2021 Q2	$332K	Hold	14,032	–	–	﹤0.01%	1825
2021 Q1	$333K	Hold	14,032	–	–	﹤0.01%	1753
2020 Q4	$281K	Hold	14,032	–	–	﹤0.01%	1802
2020 Q3	$292K	Hold	14,032	–	–	﹤0.01%	1640
2020 Q2	$246K	Hold	14,032	–	–	﹤0.01%	1779
2020 Q1	$229K	Hold	14,032	–	–	﹤0.01%	1623
2019 Q4	$289K	Hold	14,032	–	–	﹤0.01%	1779
2019 Q3	$161K	Hold	14,032	–	–	﹤0.01%	2065
2019 Q2	$185K	Sell	14,032 -28,064	-67%	-$375K	﹤0.01%	2074
2019 Q1	$637K	Buy	42,096 +28,064	+200%	+$449K	﹤0.01%	1922
2018 Q4	$241K	Hold	14,032	–	–	﹤0.01%	1803
2018 Q3	$207K	Buy	+14,032	New	+$249K	﹤0.01%	2059

Other funds holding COLL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

MetLife Investment Management's COLL Position: Q2 2026 in Review

MetLife Investment Management increased its Collegium Pharmaceutical (COLL) stake by 3.4% in Q2 2026, buying an estimated $21.6K and bringing the position to 18,958 shares worth $686K. The position accounts for ﹤0.01% of the portfolio, ranked #1742.

MetLife Investment Management first reported a position in COLL in Q3 2018 and has held it in 32 quarters since. The position peaked at $822K in Q4 2025. 279 funds tracked by Wall St. Rank hold COLL as of Q2 2026.

MetLife Investment Management held 18,958 shares of Collegium Pharmaceutical worth $686K as of Q2 2026.
MetLife Investment Management bought 632 Collegium Pharmaceutical shares in Q2 2026, an estimated $21.6K.
Collegium Pharmaceutical made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #1742 holding.
MetLife Investment Management first reported a position in Collegium Pharmaceutical in Q3 2018 and has held it in 32 quarters since.
MetLife Investment Management's Collegium Pharmaceutical position peaked at $822K in Q4 2025.
279 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.